Screener
ArriVent BioPharma, Inc. AVBP EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest and investment income | 2,791 | 2,385 |
| Net loss | (43,320) | (64,387) |
| Unrealized gain (loss) on marketable securities | (284) | 194 |
| Total other comprehensive gain (loss) | (284) | 194 |
| Total comprehensive loss | $(43,604) | $(64,193) |
| Share information: | ||
| Net loss per share attributable to common stockholders, basic and diluted | $(0.96) | $(1.90) |
| Weighted-average shares of common stock outstanding, basic and diluted | 45,067,658 | 33,898,870 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s EPS (basic)?
- ArriVent BioPharma, Inc. (AVBP) reported EPS (basic) of -$0.96 in Q1 2026.
- How has ArriVent BioPharma, Inc.'s EPS (basic) changed year-over-year?
- ArriVent BioPharma, Inc.'s EPS (basic) increased by 49.5% year-over-year, from -$1.90 to -$0.96.
- What is the long-term trend for ArriVent BioPharma, Inc.'s EPS (basic)?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s EPS (basic) has grown at a -63.7% compound annual growth rate (CAGR), from -$33.45 to -$4.41.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about ArriVent BioPharma, Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude